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Introduction
Cell death occurs through programmed or non-programmed 
processes. Programmed cell death (PCD), typically referring to 
apoptosis and autophagy, is mediated by organized intracellular 
programs, and usually occurs in biological developmental processes or 
is involved in tumor progression and response to cancer therapeutics. 
Non-programmed cell death (non-PCD), typically referring to necrosis, 
is a non-physiological and unorganized process, and usually occurs 
following acute injury and infection. Recent research has defined a 
subset of non-apoptotic/non-autophagic cell death modes that are 
controlled by specific signaling pathways that are morphologically 
distinct from apoptosis or autophagy, involving membrane rupture 
and the release of cytoplasmic contents. The view that apoptosis and 
autophagy are the sole means by which the cell can undergo PCD 
should be changed in light of the discoveries of additional modes of 
PCD, namely, programmed necrosis. Also termed regulated necrosis, 
programmed necrosis distinguishes the processes carried out by a 
specific program of genetically encoded cellular apparatuses from 
classical necrosis, which is carried out in an accidental and passive way. 
With the discovery of key mediators of necrotic death, such as receptor-
interacting serine/threonine protein (RIP) kinases and poly (ADP-
ribose) polymerases (PARPs), the concept of programmed necrosis is 
gaining ground.
Although the precise mechanisms responsible for programmed 
necrosis remain largely elusive, studies within the past 7 to 8 years have 
substantially increased our understanding of the process. Recent in 
vivo studies suggest that programmed necrosis is important for both 
physiological and pathological processes [1]. Programmed necrosis 
has unique features. Several modes of programmed necrosis have been 
identified, and their key regulators and events, such as RIP kinases, 
necrosomes, cyclophilin D, inhibition of caspases, mitochondrial 
fission, Bmf, PARP, Bax, apoptosis-inducing factor (AIF), Bcl-2 
nineteen-kilodalton interacting protein 3 (BNIP3), Nix, NADPH 
oxidases, cathepsins, and calpains, have been identified as potential 
signaling components of the necrotic program. Necroptosis is at present 
the major and most well understood form of regulated necrosis. The 
necrosome complex, composed of RIP1/3 and mixed lineage kinase 
domain-like protein (MLKL) and regulated by RIP1 and RIP3 kinases, 
is the primary cellular complex that regulates necroptosis, a major 
form of programmed necrosis. The necrosome mediates upstream 
cell death receptors and downstream executing molecules and events, 
such as reactive oxygen species (ROS) bursts, plasma membrane 
permeabilization, and cytosolic ATP reduction [2]. The cellular 
pathways involving PARP activation and AIF translocation from 
the mitochondria to the nucleus contribute to parthanatos, a second 
major programmed necrosis pathway. In addition to necroptosis and 
parthanatos, other types of programmed necrosis, such as pyroptosis, 
ferroptosis, oxytosis, pyronecrosis, ETosis, and NETosis have also been 
identified. Table 1 outlines various modes of programmed necrosis and 
their key events and regulatory machinery in comparison with other 
cell death modes.
Literature Review
In this review, we discuss each type of programmed necrosis and 
their therapeutic implications for cancer treatment purposes. Due to 
their relatively profound characterization and findings, we primarily 
focus on necroptosis and parthanatos.
Necroptosis
The most well-studied form of programmed necrosis is necroptosis 
which is typically activated in response to death receptor activation. 
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Abstract
The dogma that apoptosis and autophagy are the sole forms of Programmed Cell Death (PCD) is no longer 
accepted, due to the recent discovery of programmed necrosis, a non-apoptotic, non-autophagic form of PCD. 
Necroptosis, parthanatos, pyroptosis, and ferroptosis are all forms of programmed necrosis, as these types of 
cell death dismantle the cell in an ordered fashion that is distinctly different from apoptosis or autophagy. Several 
key cellular mediators and events in these types of PCD have been discovered. Here, we discuss the basic 
characteristics, molecular pathways, and possible implications of these lesser-known types of PCD in cancer 
treatment modalities such as chemotherapy and radiotherapy. Because resistance to apoptosis is often responsible 
for cancer treatment failures, novel therapeutic strategies that can activate alternative cell death programs have 
great appeal. Understanding the underlying mechanisms of these types of PCD may facilitate the development of 
diverse therapeutic strategies, particularly against apoptosis-resistant cancers.
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death conditions and is an essential downstream partner for RIP1 in 
necroptosis. Although some necroptosis inducers may bypass RIP1 to 
directly activate RIP3 [5], considering that necrostatin 1 inhibits both 
RIP1 and necroptosis, RIP1 may be essential for the cellular necroptotic 
program. Necroptosis requires the inactivation of caspase-8 [6], which 
leads to the activation of RIPK1 and RIPK3. Necroptosis is also linked 
to rapid mitochondrial dysfunction and excessive ROS production. 
Although the mitochondrial permeability transition (MPT) pore is 
thought to contribute to both apoptotic and necrotic cell death, the MPT 
pore may be more pro-necrotic than pro-apoptotic. It is increasingly 
suggested that while mitochondrial outer membrane permeabilization 
(MOMP) is preferentially involved in apoptosis, the mitochondrial 
permeability transition (MPT) is involved in necroptosis. MPT pore 
opening and loss of mitochondrial membrane potential (MMP) trigger 
ROS release, which can then contribute to necroptosis. However, under 
certain situations, ROS and c-Jun N-terminal kinase (JNK) may also 
be involved upstream of mitochondria, triggering MMP loss and 
subsequent necroptosis.
Historically, the most well-studied mode of necroptotic cell death 
is TNFα-mediated necroptosis. In necroptotic signaling, TNFα binding 
to TNFR1 induces the formation of a membrane-bound pro-survival 
complex, which includes TNFR-associated death domain (TRADD), 
RIP1, and several ubiquitin E3 ligases, including cellular inhibitor of 
apoptosis proteins (cIAPs). In this complex, RIP1 is polyubiquitinated 
by cIAP1 and 2. Lysine 63 ubiquitination of RIP1 contributes positively 
to TNFα-induced survival signaling by facilitating the recruitment of 
kinases that activate the nuclear factor kappa B (NF-κB) and mitogen-
activated protein kinase (MAPK) signaling pathways [4]. Ubiquitinated 
RIP1 also inhibits the formation and activation of RIP1-dependent 
apoptotic and necroptotic complexes, which is associated with cell 
survival by preventing RIP1 from interacting with the apoptotic or 
necrotic complexes. Cylindromatosis-mediated deubiquitination of 
RIP1 shifts cell fate from survival to death through the repression of 
NF-κB activation and through interactions with the proapoptotic 
machinery, such as caspase-8. Activated caspase-8 cleaves and 
inactivates RIP1 and RIP3 to block necroptosis and induce apoptosis. 
However, under certain conditions, such as caspase inhibition, RIP1 
and its sister kinase RIP3 are not cleaved, and form the necrosomal 
complex. Therefore, caspase-8-mediated degradation of RIP1 may 
represent one of the major molecular switches between apoptosis and 
necroptosis. Although the exact relationship between RIP1 and RIP3 
The term necroptosis arose from its unique characteristics combining 
apoptotic and necrotic features. Like apoptosis, necroptosis is carried 
out by a series of organized cellular components. As in necrosis, the 
ultimate stage of a necroptotic process is the swelling and rupture of 
the cell membrane, releasing damage-associated molecular patterns 
(DAMPs). Recently, a number of studies have provided new insights 
into the molecular regulation of necroptosis.
Although ligands such as Fas ligand (FasL) and tumor necrosis 
factor alpha (TNFα) stimulate apoptosis, they also kill cells in a non-
apoptotic manner with a necrotic morphology in other situations. 
This death receptor-specific necrotic death was designated necroptosis 
[3]. Necroptosis mainly occurs downstream of death receptors and is 
activated by the ligation of death ligands such as TNFα, TNF-related 
apoptosis-inducing ligand (TRAIL), and FasL, to their cognate 
receptors, including the TNF receptor superfamily members TNF 
receptor (TNFR), TRAIL receptor (TRAILR), TNF-related weak 
inducer of apoptosis (TWEAK), lymphotoxic beta (LTβ) receptor, and 
Fas. Ligand-receptor binding results in the assembly of a supramolecular 
complex composed of caspase-8, the adaptor protein Fas-associated 
death domain (FADD), and RIP1/3. In this type of cell death, RIP1 plays 
a role in the branch point between survival and death [4]. When RIP1 
is ubiquitinated, it induces survival signals. In contrast, when RIP1 is 
deubiquitinated, it induces apoptotic or necrotic signals depending on 
the action of caspase-8. Under conditions in which caspase-8 function 
is favored, active caspase-8 cleaves RIP1/3 and inactivates them, 
triggering apoptosis. However, when caspases are inactivated, the 
proteolytic cleavage of RIP1 and RIP3 is inhibited, thereby leading to 
RIP1/3 activation and resultant necroptosis. Induction of necroptosis 
can also occur independently of death receptor pathways through 
the engagement of pattern recognition receptors, such as interferon 
receptors and Toll-like receptors (TLR3 and TLR4), and viral expression 
of RIP homotypic interaction motif (RHIM)-containing proteins. In 
addition, genotoxic or oxidative stress induced by anticancer drugs, 
ionizing radiation, photodynamic therapy, ischemia-reperfusion injury, 
or calcium overload have been described as initiators of necroptosis. A 
variety of stimuli have been implicated as initiators of necroptosis, and 
the list of necroptotic triggers is constantly growing.
Necroptosis is initiated by the necroptosome, a protein complex 
that contains RIP1 and RIP3. RIP1 kinase activity is required for 
death receptor- and caspase inhibitor-mediated necroptosis in both 
murine and human cells. RIP3 interacts with RIP1 under necrotic cell 
Table 1: Overview and comparison of various cell death pathways.
Variables Programmed Non-
programmed
Apoptosis Autophagy Programmed necrosis Necrosis
Necroptosis Parthanatos Pyroptosis Ferroptosis
Trigger Death receptor Starvation Death receptor 
activation and inhibition 
of caspase-8
Genotoxic stress Inflammasomes Experimental 
compounds
Infection
Intrinsic Rapamycin Excitotoxicity Clinical drugs Toxins
Trauma
Inflammatory 
response
No Yes Yes Yes Yes Yes Yes
Aspects Chromatin 
condensation
Membrane blebbing Mitochondrial swelling Chromatin 
condensation
Cell swelling Increased 
Membrane 
density
Mitochondrial 
swelling
Nuclear fragmentation Autophagic vacuoles Cell swelling Nuclear 
fragmentation
Membrane rupture Small 
mitochondria
Cell swelling
Apoptotic body Increased lyssomal 
activity
Membrane rupture Maintained 
Mitochondrial integrity
Membrane 
ruptureMembrane blebbing
Key
regulators
Cytochrome c
Caspases
Atg proteins
Beclin-1
RIP 1/3
MLKL
PARPs
AIF
Caspase-1/4/5/11
Gasdermin D
GPX4 −
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remains to be clarified, RIP1 and RIP3 phosphorylate and activate each 
other [7-9]. Both RIP1 and RIP3 contain kinase domains, but RIP3 
lacks the death domain typically involved in the recruitment of proteins 
to death receptors. RIP1 interacts with and recruits RIP3 through 
a homotypic interaction motif (RHIM) at the C-terminal end of the 
intermediate domain contained within both proteins [10], resulting in 
their mutual phosphorylation.
Stable formation of the necrosome, the complex containing RIP1, 
RIP3, and associated proteins, depends on RIP1 kinase activity [7,8]. 
RIP1 kinase activity is also responsible for RIP3 phosphorylation. 
RIP1-induced RIP3 phosphorylation results in RIP3 oligomerization, 
which is necessary for its activation. MLKL is a well-identified 
substrate of RIP3. The interaction between RIP3 and MLKL is 
dependent upon the kinase activity of RIP3 and its phosphorylation at 
Ser227 [11]. RIP3 phosphorylates MLKL at both Thr357 and Ser358, 
and these phosphorylation events are required for MLKL action 
[11]. Phosphorylated MLKL trimerizes, translocates to the plasma 
membrane, and causes necrotic membrane permeabilization and 
disruption, which are crucial for necroptosis [12]. In the pro-necrotic 
necrosome complex, RIP3 interacts with several bioenergetic enzymes, 
including glycogen phosphorylase (PYGL), glutamate-ammonia ligase 
(GLUL), and glutamate dehydrogenase 1 (GLUD1), thereby enhancing 
metabolism accompanied by increased ROS production. The prevalence 
of the association of RIP3 with metabolic enzymes suggests that RIP3 
may regulate energy production pathways associated with glycolysis 
and mitochondria. Upregulation of metabolic pathways may lead to the 
generation of ROS and impact mitochondrial function.
As in apoptosis, both mitochondria and lysosomes play pivotal 
roles in the propagation of the necroptotic death signal, and the main 
downstream target of the necroptosis pathway may be mitochondrial 
fragmentation. RIP1 or RIP3 localizes to the mitochondria in 
response to a necrotic stimulus [13,14]. Phosphoglycerate mutase 
family member 5 (PGAM5) and Drp1 proteins, as well as MLKL, 
may connect the necrosome to the mitochondria, thereby inducing 
mitochondrial fission, ROS generation, MMP loss, and resultant 
necrotic cell death in TNFα-treated cells. PGAM5 is recruited to the 
necrosome and activated, and activated PGAM5 recruits and activates 
Drp1 by dephosphorylating it. Additionally, given that the knockdown 
of Bmf, a BH3-only protein, blocks necroptosis induced by the 
combination of TNFα and caspase inhibition [15], Bmf is also one of 
the surprising candidates discovered as a mediator of TNFα-induced 
necroptosis. Although the exact molecular mechanisms by which Bmf 
promotes necroptosis versus apoptosis remain to be clarified, Bmf is a 
component of the core machinery of necroptosis. Necroptosis induced 
by TNFα occurs together with, and requires the production of, ROS. 
Mitochondrial and lysosomal ROS, as well as ROS generated by NADPH 
oxidases all contribute to necroptotic events. ROS and JNK activation 
are causatively related, and TNFα-induced necroptosis involves ROS 
generation and JNK activation. ROS- and JNK-dependent signaling 
events can result in the loss of MMP via the opening of the MPT pore, 
resulting in a loss of ATP production and mitochondrial rupture.
Parthanatos
Genotoxic stress-induced DNA damage causes necrotic cell death 
that is associated with an overstimulation of PARPs. Parthanatos, 
another type of programmed necrotic cell death, is characterized by, and 
dependent on, overactivation of the DNA damage-responsive nuclear 
PARP enzymes, and subsequent ATP depletion and translocation of 
AIF from the mitochondrial intermembrane space to the nucleus [16-
18]. Cyclophilin D, lysosomal proteases such as cathepsins, and non-
lysosomal proteases such as calpains are also involved in parthanatos. 
This form of cell death has been implicated in a range of diseases, 
including Parkinson’s disease, Alzheimer’s disease, Huntington’s 
disease, stroke, diabetes, and heart attacks. PARPs transfer the ADP-
ribose moiety of NAD+ to amino acids, thereby placing PAR polymers 
on various substrate proteins. PARP-mediated parthanatos is reportedly 
dependent on mitochondrial translocation of Bax [17]. Bax in turn 
induces parthanatos by releasing AIF from the mitochondria. Necrosis 
induced by hyperactivation of PARPs is simply due to metabolic 
catastrophe, in which the overactive PARPs use up cellular supplies 
of NAD+ and subsequent ATP. In addition to DNA damage-mediated 
necrotic death, PARPs also contribute to necrotic cell death initiated 
by TNFα and TRAIL. The parthanatic pathway not only interacts with 
the necrosome-associated pathway, but is also executed independently.
DNA damage-activated PARPs, particularly PARP1, drive necrotic 
cell death through multiple factors [19]. First, PARPs catalyze the 
polymerization of ADP-ribose units from donor NAD+ molecules 
on target proteins, resulting in NAD+ depletion [20]. In an effort to 
restore NAD+ levels, ATP is consumed, thereby depleting cellular 
ATP. Second, because NAD+ is an important cofactor for glycolysis, 
NAD+ depletion also inhibits glycolysis and prevents the formation of 
pyruvate and other downstream substrates of mitochondrial respiration 
pathways. Slowed glycolysis leads to a reduction in ATP production, 
as another ATP depletion mechanism. Third, the depletion of NAD+ 
promotes MPT pore opening-induced mitochondrial membrane 
depolarization, interfering with ATP production. Lastly, the PAR 
polymer produced by PARPs is itself cytotoxic by binding to AIF and 
inducing mitochondrial discharge of AIF [21]. Released AIF can cause 
DNA breaks, and AIF-mediated DNA degradation further activates 
PARPs, thereby initiating a vicious cycle. PARP-induced parthanatos 
is also dependent on the activation of Ca2+-activated calpains, which 
in turn impinge upon mitochondria [17]. Calpains favor the release of 
AIF from mitochondria, as well as the spillage of lysosomal cathepsins 
into the cytosol [22].
Other Types of Programmed Necrosis
Besides necroptosis and parthanatos, additional regulated forms 
of necrosis have been described, such as pyroptosis and feroptosis. 
Pyroptosis is a highly inflammatory form of programmed necrosis 
caused by various pathological stimuli, such as cancer, stroke, and heart 
attack, and is vital for controlling microbial infection. It is also triggered 
by cancer therapy. Inflammatory caspases, such as caspase-1, -4, -5, and 
-11, are involved in this type of cell death. Pyroptosis is initiated by 
the formation and activation of multi-protein complex inflammasomes. 
Recently identified Gasdermin D, a component of inflammasomes and 
a substrate of inflammatory caspases, is also required for pyroptosis 
[23,24].
Ferroptosis is another form of programmed necrotic cell death 
implicated in diverse degenerative diseases such as tissue ischemia/
reperfusion injury and Parkinson’s disease. This form of cell death 
results from intracellular iron-dependent accumulation of lethal ROS 
and is characterized by lipid peroxidation. Ferroptotic cells display 
subtler morphological features, including smaller than normal 
mitochondria with condensed mitochondrial membrane density 
and outer mitochondrial membrane rupture. This form of cell death 
is caused by decreased activity of the lipid repair enzyme glutathione 
peroxidase 4 (GPX4), a key inhibitor of ferroptosis, and subsequent 
accumulation of lipid peroxides [25,26].
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The Implications of Programmed Necrosis for Cancer 
Therapy
Given the rising significance of necrosis, especially programmed 
necrosis, in cancer, a better understanding of its implications in 
cancer development and maintenance is a prerequisite for the design 
of appropriate drugs. A growing body of evidence demonstrates that 
necroptosis is deregulated in cancer (Figure 1). For example, somatic 
mutations in RIP1, RIP3, and MLKL genes have been observed in 
human cancers. Single nucleotide polymorphisms in the RIP1 and 
RIP3 genes were detected in chronic myeloid leukemia and non-
Hodgkin’s lymphoma patients, respectively [27,28]. Multiple cancers, 
including solid cancer cells, show suppressed RIP3 expression. RIP3 
may be silenced by methylation in various cancer cell lines [29]. 
Necrotic regulators also seem to affect cancer prognosis. For example, 
low RIP3 levels are correlated with poor outcomes in colorectal and 
breast cancer patients [30-32]. RIP3 expression in the hematopoietic 
system may limit cancer invasion and metastasis. Likewise, reduced 
MLKL expression is significantly associated with decreased overall 
survival in gastric, ovarian, cervix, colon, and pancreatic cancers 
[33-37]. Thus, RIP3 and MLKL expression could potentially serve as 
prognostic biomarkers for these cancers. Overall, these studies suggest 
that programmed necrosis may play a tumor suppressive role in cancer. 
However, because the expression of necrotic players is elevated in some 
cancers, it is difficult to generalize the tumor suppressive activities of 
these regulators.
Therapeutic interventions that aim to induce apoptosis often face 
resistance arising from the activation of survival pathways. Thus, 
finding another cell death modality and more thoughtful combination 
therapies that simultaneously target alternative cell death and survival 
pathways is the main focus in cancer research. Triggering programmed 
necrosis could be useful when drugs fail to induce apoptosis. Targeting 
necroptosis and other types of programmed necrosis has been proposed 
as an emerging and attractive anti-tumor treatment strategy bypassing 
acquired apoptotic resistance and potentially switching on antitumor 
responses. In this section, we confine our description to necroptosis-
based cancer therapy, due to its relatively well-documented findings.
Because a variety of cancer cell lines have necroptotic machinery 
and can undergo necroptosis, necroptotic therapy shows promise. 
Colorectal cancer cells and hematopoietic neoplasm cells seem 
particularly sensitive and responsive to necroptosis inducers [38]. 
However, other cancer cell lines, such as HeLa cervical cancer 
cells, HCT116 colorectal cancer cells, and OVCAR4 ovarian cancer 
cells, which lack effective necroptotic machinery, are unsuitable for 
necroptotic-based cancer therapy [38]. Furthermore, necroptosis-
sensitive cells tend to only be responsive to a few specific necroptosis 
inducers rather than all necroptosis inducers. Necroptosis can be 
induced by cellular metabolic and genotoxic stress as well as ligand-
receptor binding. A growing list of anticancer compounds with various 
mechanisms of action have been reported to initiate necroptosis in 
cancer cells. The strategies to induce necroptosis in cancer treatment are 
varied, and include classical necroptosis inducers, chemotherapeutic 
agents, ionizing radiation, and natural compounds (Figure 2). 
Necroptosis is induced by chemotherapy, and is sometimes at least 
partially responsible for the toxicity of chemotherapeutic agents. RIP3 
expression is required to sensitize a limited number of cancer cell lines 
to DNA-damaging agents in cancer chemotherapy. Necroptosis also 
plays an important role in radiation-induced cell death in endocrine 
cancers, including anaplastic thyroid cancers and adrenocortical 
cancers [39]. Treatment with necrostatin, a pharmacological inhibitor of 
RIP1, increases radioresistance in these cancer cell lines by enhancing 
DNA repair capacity. Moreover, necroptosis may be induced by natural 
compounds. Several reports suggest that shikonin, a major component 
of the Chinese herbal medicine zicao, kills cancer cells through the 
necroptosis pathway [40,41].
Necroptosis triggers the anticancer immune response, which is 
another cancer-killing mechanism. Necrosis is believed to be more 
immunogenic than apoptosis. Combining caspase inhibitors with 
radiotherapy or chemotherapy reduces tumor growth due to the 
recruitment of immune cells. The ability of necroptosis to recruit 
and activate immune cells at tumor sites may increase the efficacy of 
the immune checkpoint blockade. Necroptotic cancer cells produce 
cytokines in a RIP1-dependent manner and release DAMPs that 
stimulate and attract dendritic cells to tumor sites. RIP3 induces the 
expression of cytokines that can activate natural killer T cells for 
Figure 2: Various anticancer strategies targeting molecules involved in the 
programmed necrotic pathway.
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Figure 1: Deregulation of components of the programmed necrotic pathway.
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anti-tumor activity. In contrast to RIP1 and RIP3, MLKL seems to 
be dispensable for cytokine synthesis [42,43]. Necroptosis may also 
be induced by autophagy. The BMI-1 inhibitor PTC-209 induces 
autophagy and upregulates RIP3, leading to necroptosis in ovarian 
cancer cells [44], indicating the existence of crosstalk between the 
autophagic and necroptotic machineries. Depletion of cIAP1/2 by 
second mitochondria-derived activator of caspase (Smac) mimetics 
deubiquitinates and unleashes RIP1 from its scaffolding pro-survival 
function and induces its recruitment to the ripoptosome, a complex 
that serves as a platform for regulating apoptosis or necroptosis. After 
that, RIP1 determines cell fate by regulating caspase-8-mediated 
apoptosis or promoting RIP3-MLKL-dependent necroptosis, which 
is dependent on the action of caspase-8. The specific induction of 
necroptosis requires the coordination of RIP kinase activation and 
caspase-8 inhibition. Therefore, simultaneously targeting IAPs and 
caspase-8 through genetic deletion or pharmacological inhibition using 
a combination of Smac mimetics and caspase inhibitors can specifically 
and unequivocally lead to necroptosis in cancer cells that have intact 
caspase-8 function.
Discussion and Perspectives
Dysfunction and/or disruption of apoptotic machinery appear to be 
critical factors in intrinsic and acquired drug resistance in cancer cells. 
The failure of cancer cells to undergo apoptosis is a major problem 
in cancer treatment strategies. Therefore, novel therapeutic concepts 
to reactivate other cell death programs in human malignancies are 
needed. Programmed necrosis is a cell death modality that is controlled 
by defined signal transduction pathways. The deregulation of the 
programmed necrotic pathway observed in several cancers implicates 
it in cancer progression. Although little is known about the precise 
molecular targets in the programmed necrotic signaling pathway that 
are engaged by individual compounds, targeting programmed necrosis 
may be a plausible therapeutic intervention for activating another death 
pathway and/or boosting the immune system. Because programmed 
necrosis and apoptosis use distinct molecular pathways, triggering 
this regulated form of necrosis could be a particularly effective 
alternative method for eradicating apoptosis-resistant cancer cells. The 
requirement of caspase inhibition for effectively activating programmed 
necrosis represents a paradigm shift in cancer therapy, as most current 
therapeutic strategies aim to activate caspases. Because treatment 
resistance is among the most challenging currently unsolved problems 
in oncology, therapeutic induction of programmed necrosis may pave 
the way toward novel and more efficient treatment approaches.
Conclusion
It is still unknown whether programmed necrosis is a tolerable 
and feasible therapeutic target, or just a conceptual model. Although 
targeting programmed necrosis for cancer treatment presents several 
advantages over current strategies, a greater understanding of this type 
of therapeutic pathway is essential to assess the clinical achievability, 
as there is concern about this strategy due to the intrinsic or acquired 
defects of programmed necrotic machinery observed in many cancer 
cells. Two other concerns are whether programmed necrosis inducers 
selectively kill cancer cells without disturbing normal cells, and 
whether repetitive induction of programmed necrosis may lead to the 
development of chronic inflammatory diseases. A deeper understanding 
of the genetic and epigenetic context of programmed necrosis regulators 
will facilitate the development and administration of new mechanism-
based therapeutics.
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